INSERM U955 Equipe 7, Departments of Urology and Pathology, CHU Henri Mondor, APHP, Créteil, France.
Eur Urol. 2014 Jan;65(1):154-61. doi: 10.1016/j.eururo.2012.05.049. Epub 2012 Jun 9.
The debate on the optimal number of prostate biopsy core samples that should be taken as an initial strategy is open.
To prospectively evaluate the diagnostic yield of a 21-core biopsy protocol as an initial strategy for prostate cancer (PCa) detection.
DESIGN, SETTING, AND PARTICIPANTS: During 10 yr, 2753 consecutive patients underwent a 21-core biopsy scheme for their first set of biopsy specimens.
All patients underwent a standardized 21-core protocol with cores mapped for location.
The PCa detection rate of each biopsy scheme (6, 12, or 21 cores) was compared using a McNemar test. Predictive factors of the diagnostic yield achieved by a 21-core scheme were studied using logistic regression analyses.
PCa detection rates using 6 sextant biopsies, 12 cores, and 21 cores were 32.5%, 40.4%, and 43.3%, respectively. The 12-core procedure improved the cancer detection rate by 19.4% (p=0.004), and the 21-biopsy scheme improved the rate by 6.7% overall (p<0.001). The six far lateral cores were the most efficient in terms of detection rate. The diagnostic yield of the 21-core protocol was >10% in prostates with volume >70 ml, in men with a prostate-specific antigen level<4 ng/ml, with a prostate-specific antigen density (PSAD) <0.20 ng/ml per gram. A PSAD <0.20 ng/ml per gram was the strongest independent predictive factor of the diagnostic yield offered by the 21-core scheme (p<0.001). The 21-core protocol significantly increased the rate of PCa eligible for active surveillance (62.5% vs 48.4%; p=0.036) than those detected by a 12-core scheme without statistically increasing the rate of insignificant PCa (p=0.503).
A 21-core biopsy scheme improves significantly the PCa detection rate compared with a 12-core protocol. We identified a cut-off PSAD (0.20 ng/ml per gram) below which an extended 21-core scheme might be systematically proposed to significantly improve the overall detection rate without increasing the rate of detected insignificant PCa.
关于初始策略下应采取多少前列腺活检核心样本的最佳数量的争论仍在继续。
前瞻性评估 21 芯活检方案作为前列腺癌 (PCa) 检测初始策略的诊断效果。
设计、设置和参与者:在 10 年内,2753 例连续患者接受了 21 芯活检方案作为其首次活检标本。
所有患者均接受标准化的 21 芯方案,对活检芯的位置进行定位。
采用 McNemar 检验比较每种活检方案(6、12 或 21 芯)的 PCa 检出率。使用逻辑回归分析研究了 21 芯方案诊断效果的预测因素。
6 个六分区活检、12 个芯和 21 个芯的 PCa 检出率分别为 32.5%、40.4%和 43.3%。12 芯方案使癌症检出率提高了 19.4%(p=0.004),21 芯方案总体上提高了 6.7%(p<0.001)。最外侧的 6 个芯在检测率方面效率最高。21 芯方案在前列腺体积>70ml、前列腺特异性抗原(PSA)水平<4ng/ml、PSA 密度(PSAD)<0.20ng/ml/g 的患者中的诊断效果>10%。PSAD<0.20ng/ml/g 是 21 芯方案诊断效果的最强独立预测因素(p<0.001)。21 芯方案比 12 芯方案显著增加了适合主动监测的 PCa 比例(62.5%比 48.4%;p=0.036),而不会显著增加检出的非显著性 PCa 比例(p=0.503)。
与 12 芯方案相比,21 芯活检方案显著提高了 PCa 的检出率。我们确定了一个截断 PSA(0.20ng/ml/g)值,低于该值时,建议系统地采用扩展的 21 芯方案,以显著提高整体检出率,而不会增加检出的非显著性 PCa 比例。